Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anecortave acetate.

Sophie J Bakri1, Peter K Kaiser

  • 1Cole Eye Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk i3, Cleveland, OH 44195, USA.

Expert Opinion on Investigational Drugs
|January 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality Improvement in Vitreoretinal Surgery: Single-Center Report on Utility of Routine Intravenous Fluids in Pars Plana Vitrectomy.

Journal of vitreoretinal diseases·2026
Same author

EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study: Erratum.

Retina (Philadelphia, Pa.)·2026
Same author

Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Tyrosine kinase inhibitors for wet age-related macular degeneration: The current developmental landscape.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Swept-Source OCT and OCT Angiography B-Scan Analysis of Inflammatory Retinal Vascular Changes: Quantitative and Qualitative Assessment.

Ophthalmology. Retina·2026
Same author

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.

Eye (London, England)·2025

Anecortave acetate suspension is a novel treatment for age-related macular degeneration. Clinical trials show its effectiveness in treating subfoveal choroidal neovascularization, with ongoing studies for dry and wet forms.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Biomedical Science

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Current treatments for wet AMD have limitations.
  • Anecortave acetate (PAX) is a novel angiostatic corticosteroid with potential therapeutic applications.

Purpose of the Study:

  • To review the pharmacotherapeutics of anecortave acetate suspension.
  • To summarize clinical trial data for anecortave acetate in AMD treatment.
  • To discuss ongoing research for dry and wet AMD.

Main Methods:

  • Review of existing literature on anecortave acetate.
  • Summary of multi-center, randomized, controlled clinical trials.
  • Analysis of pharmacokinetics and pharmacodynamics data.

Related Experiment Videos

Main Results:

  • Anecortave acetate demonstrates angiostatic properties.
  • Clinical trials indicate efficacy in treating subfoveal choroidal neovascularization in wet AMD.
  • Safety and tolerability profiles are being evaluated in ongoing trials.

Conclusions:

  • Anecortave acetate suspension is a promising therapeutic agent for AMD.
  • Further research is warranted to establish its role in managing both wet and dry AMD.
  • Ongoing trials will provide more comprehensive data on long-term efficacy and safety.